维鲁布林及其衍生物:突林向癌症治疗的进展和前景
Alireza Mousavi1, Mahfam Moradi1, Loghman Firoozpour2
1Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
European journal of medicinal chemistry
|September 12, 2025
概括
维鲁布林是一种有前途的抗癌药物,用于质母细胞瘤治疗,向微管. 目前正在进行的研究优化了其衍生品,以提高有效性,进入大脑,并作为诊断成像剂的潜在用途.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 维鲁布林 (MPC-6827) 是一种微小管体破坏稳定的药物,向管素上的菌素部位.
- 它通过诱导线粒体停止,在质母细胞瘤和多抗药性癌症中表现出有效性.
研究的目的:
- 审查基于维鲁布林的化合物的药理概况,临床发展和结构演变.
- 突出维鲁布林在推进布林向癌症治疗中的作用.
- 讨论在瘤学和诊断中使用维鲁布林衍生物的未来前景.
主要方法:
- 关于维鲁布林及其衍生物的综合文献综述.
- 对药理学数据,临床试验结果和结构修改的分析.
- 基于分子性质的诊断应用的探索.
主要成果:
- 维鲁布林衍生物已被优化,以提高功效,选择性,代谢稳定性和大脑透.
- 维鲁布林的机制涉及干扰微管体动力学和诱导细胞循环停止.
- 它的特性也支持它作为一种针对大脑的分子成像剂.
结论:
- 维鲁布林代表了下一代抗癌药物的宝贵支架,特别是在神经瘤学中.
- 进一步开发维鲁布林衍生物有望改善治疗和诊断应用.
- 新的基于维鲁布林的候选药物可能很快进入临床评估.
更多相关视频
相关概念视频
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Destabilization of Microtubules
3.5K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.5K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


